Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention

Clinical Cardiology

Volumn 33, Issue 11, 2010, Pages 686-692

  Koutouzis, Michael ^a   Lagerqvist, Bo ^b   Oldgren, Jonas ^b   Åkerblom, Axel ^b   Wahlin, Magnus ^a   Karlsson, Thomas ^a   Albertsson, Per ^a   Matejka, Göran ^a   Grip, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG COST; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STROKE; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; COST SAVINGS; DRUG COSTS; DRUG SUBSTITUTION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649654661     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20814     Document Type: Article

References (25)

1. Lincoff AM, Califf RM, Moliterno DJ, et al., Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341: 319-327.
2. Blankenship JC, Tasissa G, O' Shea JC, et al,; ESPRIT Investigators. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001; 38: 653-658.
3. Karvouni E, Katritsis DG, Ioannidis JP, Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41: 26-32.
4. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association;, Antman EM, Hand M, Armstrong PW, et al., 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2008 51: 977]. J Am Coll Cardiol 2008; 51: 210-247.
5. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2008; 51: 974.
6. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al., ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: 216-235.
7. Stone GW, Grines CL, Cox DA, et al,; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-966.
8. Montalescot G, Barragan P, Wittenberg O, et al,; ADMIRAL Investigators (Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up). Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903. (Pubitemid 32553358)
9. O' Shea JC, Hafley GE, Greenberg S, et al,; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468-2473.
10. Zeymer U,. Eptifibatide versus abciximab in primary PCI for ST-elevation myocardial infarction. EVA-AMI trial. Accessed November 4, 2007.
11. PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2001; 141: 402-409.
12. Topol EJ, Moliterno DJ, Herrmann HC, et al,; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894.
13. Wahlin M, Albertsson P, Karlsson T, et al., Switch from abciximab to eptifibatide during percutaneous coronary intervention. Int J Cardiol 2009; 134: 393-400.
14. Lagerqvist B, James SK, Stenestrand U, et al,; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
15. Coons JC, Seybert AL, Saul MI, et al., Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann Pharmacother 2005; 39: 1621-1626.
16. Long KH, Ting HH, McMurtry EK, et al., A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions. Value Health 2008; 11: 462-469.
17. Deliargyris EN, Upadhya B, Applegate RJ, et al., Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. J Invasive Cardiol 2004; 16: 611-616.
18. Schweiger MJ, Changezi HU, Naglieri-Prescod D, et al., Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin Ther 2003; 25: 225-234.
19. Leung VW, Sunderji R, Zed PJ, et al., Switching from abciximab to eptifibatide for percutaneous coronary interventions: a local analysis (SWAP study). Can J Cardiol 2003; 19: 809-814.
20. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-961.
21. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigation. N Engl J Med 1997; 336: 1689-1696.
22. EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
23. Mehilli J, Kastrati A, Schulz S, et al,; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009; 119: 1933-1940.
24. De Luca G, Suryapranata H, Stone GW, et al., Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-1765.
25. Montalescot G, Antoniucci D, Kastrati A, et al., Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007; 28: 443-449.